Cosmetic psychopharmacology of anxiety: Bioethical considerations Dan J. Stein Invited Commentary Pages: 237 - 238
Risperidone for chronic combat-related posttraumatic stress disorder Dan J. SteinPaul D. CareyJonathan Ipser Clinical Trials Report Pages: 243 - 243
Risperidone for posttraumatic stress disorder related to childhood abuse Dan J. SteinPaul D. CareyJonathan Ipser Clinical Trials Report Pages: 243 - 243
Risperidone for irritable Aggression in posttraumatic stress disorder Dan J. SteinPaul D. CareyJonathan Ipser Clinical Trials Report Pages: 243 - 244
Anxiety and medical disorders Jacqueline E. MullerLiezl KoenDan J. Stein OriginalPaper Pages: 245 - 251
Predictors of pharmacotherapy response in anxiety disorders Damiaan DenysFemke de Geus OriginalPaper Pages: 252 - 257
Cognitive behavioral therapy for obsessive-compulsive disorder: An update Jonathan D. HuppertMartin E. Franklin OriginalPaper Pages: 268 - 273
Effects of psychologic stress on fetal development and pregnancy outcome D. KoubovecL. GeertsB. Vythilingum OriginalPaper Pages: 274 - 280
Treatment of substance use disorders in schizophrenia: A unifying neurobiological mechanism? Robert M. RothMary F. BrunetteAlan I. Green OriginalPaper Pages: 283 - 291
Brain maturation and its relevance to understanding criminal culpability of juveniles Ruben C. Gur OriginalPaper Pages: 292 - 296
First- and second-generation antipsychotic medication and cognitive processing in schizophrenia Thomas W. WeickertTerry E. Goldberg OriginalPaper Pages: 304 - 310
Diagnosing schizophrenia circa 2005: How and why? Laurie M. McCormickMichael Flaum OriginalPaper Pages: 311 - 315
Recovery in schizophrenia: Reality or mere slogan Natalie B. SlopenPatrick W. Corrigan OriginalPaper Pages: 316 - 320